医学
特应性皮炎
皮肤病科
贾纳斯激酶
发病机制
临床试验
疾病
免疫系统
免疫学
内科学
细胞因子
作者
Maddalena Napolitano,Luigi Fornaro,Luca Potestio,Gabriella Fabbrocini,Cataldo Patruno
出处
期刊:Drugs of Today
日期:2022-01-01
卷期号:58 (8): 373-373
被引量:1
标识
DOI:10.1358/dot.2022.58.8.3408817
摘要
Atopic dermatitis (AD) is an inflammatory chronic-relapsing skin disease affecting approximately 15% to 20% of children and 10% of adults in industrialized countries. Both loss of epidermal barrier permeability and immune dysregulation seem to be the most important actors in AD pathogenesis. Several studies have demonstrated the role of Janus kinase (JAK) enzymes in AD pathogenesis suggesting oral and topical JAK inhibitors as new emerging therapies for AD. Among the JAK inhibitors, abrocitinib is an oral JAK1-selective inhibitor. The aim of this study is reviewing current literature about the efficacy and safety of abrocitinib in AD. The literature search was carried out considering the main search engines relating to medical literature and clinical trials. The efficacy and safety of abrocitinib have been confirmed in several studies suggesting this drug as a valuable treatment for moderate to severe AD.
科研通智能强力驱动
Strongly Powered by AbleSci AI